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ABSTRACT: Epilepsy is the most common neurological disorder,
with over 50 million people worldwide aﬀected. Recent evidence
suggests that the transient receptor potential cation channel subfamily
V member 1 (TRPV1) may contribute to the onset and progression of
some forms of epilepsy. Since the two nonpsychotropic cannabinoids
cannabidivarin (CBDV) and cannabidiol (CBD) exert anticonvulsant
activity in vivo and produce TRPV1-mediated intracellular calcium
elevation in vitro, we evaluated the eﬀects of these two compounds on
TRPV1 channel activation and desensitization and in an in vitro model
of epileptiform activity. Patch clamp analysis in transfected HEK293
cells demonstrated that CBD and CBDV dose-dependently activate
and rapidly desensitize TRPV1, as well as TRP channels of subfamily V
type 2 (TRPV2) and subfamily A type 1 (TRPA1). TRPV1 and TRPV2 transcripts were shown to be expressed in rat
hippocampal tissue. When tested on epileptiform neuronal spike activity in hippocampal brain slices exposed to a Mg2+-free
solution using multielectrode arrays (MEAs), CBDV reduced both epileptiform burst amplitude and duration. The prototypical
TRPV1 agonist, capsaicin, produced similar, although not identical eﬀects. Capsaicin, but not CBDV, eﬀects on burst amplitude
were reversed by IRTX, a selective TRPV1 antagonist. These data suggest that CBDV antiepileptiform eﬀects in the Mg2+-free
model are not uniquely mediated via activation of TRPV1. However, TRPV1 was strongly phosphorylated (and hence likely
sensitized) in Mg2+-free solution-treated hippocampal tissue, and both capsaicin and CBDV caused TRPV1 dephosphorylation,
consistent with TRPV1 desensitization. We propose that CBDV eﬀects on TRP channels should be studied further in diﬀerent in
vitro and in vivo models of epilepsy.
KEYWORDS: Cannabinoid, TRP channels, epilepsy, patch clamp, multi electrode arrays (MEAs)
E pilepsies represent a subset of neuronal dysrhythmiascaused by, among others, defects in membrane excitability,
which leads to the aberrant synchronization of neural networks.
This disturbance in the electrical activity is characterized by a
long-term risk of recurrent seizures.1 The incidence of epilepsy
in the developed world is remarkably high. The number of
people aﬀected worldwide is more than 50 million (>1.0%),
with an incidence of 20−70 new cases/10 000 individuals. The
majority of new cases occur most frequently in infants and the
elderly.2,3 To date, epilepsy cannot be cured; except for a small
minority of cases that can be approached surgically, the
treatment of epilepsy is largely based on the use of antiepileptic
drugs (AEDs) to achieve symptomatic seizure control.
Currently, about 70% of people with epilepsy can be
successfully treated by the large spectrum of AEDs available,
each with discrete pharmacokinetics, spectrum of antiepileptic
activity, and toxicity. The molecular targets of most of these
AEDs are restricted to voltage-gated Na+, K+, and Ca2+
channels, GABAA receptors, the GAT-1 GABA transporter,
glutamate, GABA transaminase, and synaptic proteins involved
in neurotransmitter release, such as SV2A.2 In general, current
AEDs work by changing the levels of neurotransmitters in the
brain that regulate electrical impulses. However, in spite of such
a wide therapeutic armamentarium, 30% of epileptic patients
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still do not receive satisfactory seizure control due to their
unresponsiveness to AEDs.2 Recently, we have shown that two
of the nonpsychoactive constituents of Cannabis sativa,
cannabidiol (CBD) and cannabidivarin (CBDV), which are
unrelated to current AEDs, are emerging candidates with the
potential to reduce seizures.4−8 However, the exact molecular
mechanism of the anticonvulsant action of these two
phytocannabinoids, which are currently undergoing clinical
investigation, remains to be elucidated.
Transient receptor potential (TRP) channels are a large
subfamily of ion channels characterized by weak voltage
sensitivity and a nonselective permeability to monovalent and
divalent cations including Mg2+, Ca2+, and Na+. TRP channels
are expressed throughout the body and their activation in
neurons serves to transduce chemical or physical stimuli into
nerve impulses to transmit to the brain. TRPV1, also known as
the capsaicin receptor or vanilloid receptor 1, was the ﬁrst
member of the TRPV subfamily to be discovered and cloned.9
We report, through the use of patch clamp analysis performed
in transfected HEK293 cells, that both CBD and CBDV dose-
dependently activate and rapidly desensitize TRPV1, as well as
TRPV2 and TRPA1, channels. Measurement of hippocampal
slice neuronal activity exposed to Mg2+-free solution using
multielectrode arrays (MEAs) revealed that CBDV, similar to
capsaicin, signiﬁcantly reduces amplitude of epileptiform bursts.
Further experiments indicated that CBDV eﬀects in this in vitro
model of epileptogenic activity may not be uniquely mediated
by TRPV1 channels. However, capsaicin and CBDV both
caused TRPV1 dephosphorylation and, consequentially, may
cause channel desensitization, suggesting that CBDV eﬀects on
TRP channels should be studied further in diﬀerent models of
epilepsy.
■ RESULTS AND DISCUSSION
TRPV1, TRPV2, and TRPA1 Channels Are Activated
and Rapidly Desensitized by CBDV and CBD: Whole-Cell
Patch Clamp Analysis. Some phytocannabinoids have the
potential to address the unmet clinical need associated with a
range of treatment-resistant epilepsies;6 we have shown that
both CBD and CBDV are anticonvulsant in a range of in vitro
and in vivo models4−8 and that CBDV can suppress
pentylenetetrazole (PTZ)-induced increases in epilepsy-related
gene expression.10 However, despite this preclinical and clinical
promise, the mechanisms whereby CBD or CBDV exert their
anticonvulsant eﬀects have not been elucidated. CBD and
CBDV have extremely low, physiologically irrelevant, aﬃnity
for cannabinoid CB1 receptors, and both pure CBDV and an
anticonvulsant CBDV-enriched extract have been shown to act
in a CB1-independent manner.
8 CBD has a number of diﬀerent
potential anticonvulsant molecular mechanisms.5,11 Moreover,
CBD, and the related phytocannabinoid cannibigerol (CBG)
can block voltage-gated Na+ channels in vitro but this action
does not contribute to their anticonvulsant activity, as CBG had
no eﬀect in the PTZ model of seizure.12 Previous studies have
suggested that TRP channels are molecular targets for
phytocannabinoids. We and others have shown that CBD
activates TRPV1, TRPV2, and TRPA1,13−16 while CBDV also
acts at these TRP isoforms, in some cases with slightly lower
potency.15 Here, we performed patch clamp studies with CBD
and CBDV in HEK293 cells transiently overexpressing rat
recombinant TRPV1 channels. A relatively selective agonist of
TRPV1 channels, capsaicin, at the concentrations of 1 and 10
μM, evoked a bidirectional current across the voltage range
(−80 to +80 mV), with a reversal potential near 0 mV (Figure
1a). Such data is consistent with the widely reported
nonselective cationic current activated by TRP isoforms.
Compared to vehicle (DMSO), CBDV or CBD (3, 10, and
30 μM) dose-dependently evoked a TRPV1 channel-mediated
current characterized by a bidirectional current similar to
capsaicin (Figure 1b and c). For CBDV and CBD, the current
reversal potential point was close to 0 mV (Figure 1b and c).
The normalized current density values for CBDV and CBD
were estimated by extrapolating membrane potential values at
±80, ±60, and ±40 mV (Figure 1d and e). The TRPV1
Figure 1. Eﬀects of CBDV and CBD in HEK293 transiently expressing
rat TRPV1 channels: (a) Representative traces of capsaicin (CAPS; 1−
10 μM) eﬀects in HEK293 expressing rat TRPV1 channels. (b) CBDV
(10−30 μM) and (c) CBD (10−30 μM) eﬀects on TRPV1 channel
current density compared to control (vehicle, DMSO). (d) Eﬀects of
CBDV (3−30 μM) and (e) CBD (3−30 μM) on TRPV1 current
expressed as current density relative to control at a distinct range of
membrane potentials. (f) Representative traces (upper panel) showing
capsazepine (CAPZ; 10 μM) block of CBDV (30 μM) and (g) CBD
(30 μM) eﬀect on TRPV1 currents. The bottom panels in (f) and (g)
show quantiﬁed data. Each bar is the mean ± SEM of at least four
separate determinations. *p < 0.05 vs vehicle (Students t test).
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antagonist capsazepine (CAPZ; 10 μM) abolished the eﬀects of
CBDV and of CBD, conﬁrming that these currents were
mediated by TRPV1 (Figure 1f and g). Capszepine eﬀect was
also quantiﬁed by normalizing current density values relative to
control (Figure 1f and g; bottom panel). In this system,
recombinant TRPV1 channels are rapidly desensitized upon the
second exposure to 1 μM capsaicin or 10 μM CBDV and CBD
(Figure 2a).
We next tested the eﬀects of CBDV and CBD on rat
recombinant TRPV2 channels. Similar to the eﬀects observed
for TRPV1 channels and when compared to vehicle, CBDV
and CBD (3, 10, and 30 μM) dose-dependently evoked a
bidirectional current across the voltage range (−80 to +80 mV)
with a reversal potential near to 0 mV (Figure 3a−d). CBDV-
and CBD-evoked currents were completely blocked by
ruthenium red (RR; 10 μM), a widely used TRP channel
blocker, (Figure 3e and f). TRPV2 channels were rapidly
desensitized upon second exposure to 10 μM CBD and CBDV
(Figure 2b).
Given that CBD and CBDV have previously been proposed
to activate TRPA1 channels,14 we also tested their eﬀects on rat
TRPA1, using mustard oil (MO), a selective agonist of TRPA1
channels as a positive control. As shown in Figure 4a, MO (100
μM) evoked a large TRPA1-mediated bidirectional current
which reversed direction around 0 mV. CBDV and CBD (3, 10,
and 30 μM) dose-dependently evoked a TRPA1 current, as
reﬂected by the bidirectional increased current density (Figure
4b−e). RR (10 μM) abolished the eﬀects of both CBDV and
CBD (Figure 4f and g), consistent with eﬀects on a TRP-
mediated conductance. As a negative control for this set of
experiments, as well as of those described above, CBDV and
CBD (10 μM) were both applied to untransfected HEK293
cells and shown not to evoke any detectable current above
vehicle eﬀects (Supporting Information Figure 1).
Overall, we have extended our previous intracellular Ca2+
studies14,15 by using the patch clamp technique to provide
evidence for direct interaction between CBD and CBDV with
rat TRPV1, TRPV2 and TRPA1 channels. As with intracellular
Ca2+ experiments,14,15 CBD and CBDV can act at low
micromolar concentrations to activate TRPV1, TRPV2 and
TRPA1 cation channels. Most interestingly, CBD and CBDV
activation was associated with channel desensitization on
subsequent application. TRPV1, as with other TRP channels,
is widely reported to be activated and rapidly desensitized
following prolonged exposure to canonical agonists such as
capsaicin,17−19 rendering them refractory to further stimulation.
This desensitization is thought to underlie the paradoxically
analgesic eﬀect of TRPV1 agonists17 and may explain how TRP
activation could reduce neuronal activity in diseases of neuronal
hyperexcitability, such as epilepsy.
TRPV1 and TRPV2 Expression in Rat Hippocampal
Tissue. We next investigated the expression of transcripts
encoding for TRPV1, TRPV2 and TRPA1 channels in the rat
hippocampus by means of qPCR experiments, performed with
gene-selective primers (Supporting Information Table 1).
These data revealed that the genes encoding both TRPV1
and TRPV2 are expressed in both sides of the adult rat
hippocampus (Figure 5a). By contrast, and in agreement with
the prevailing literature,20 TRPA1 mRNA expression was barely
detectable. In comparison to TRPV1 mRNA expression,
TRPV2 was expressed at signiﬁcantly higher levels, while
TRPA1 was expressed at signiﬁcantly lower levels. In keeping
with the observed TRPV1 and TRPV2 mRNA expression
proﬁle, Western blot analysis revealed that TRPV2 is more
strongly expressed than TRPV1 in rat hippocampal tissue
(Figure 5b).
TRPV1 channels are predominantly expressed in nociceptive
neurons of the peripheral nervous system, where their
activation leads to the transmission and modulation of pain-
related conditions, such as inﬂammatory thermal hyperalgesia
and neuropathic pain.21 TRPV1 expression in the CNS is more
controversial, although several studies have reported TRPV1
expression in mammalian brain regions including the
hypothalamus, cerebellum, cerebral cortex, striatum, midbrain,
hippocampus, and substantia nigra.22−27 To gain further insight
into the localization of TRPV1 channels in hippocampal
neurons, immunoﬂuorescence experiments on rat brain
cryosections revealed that, in the CA1 region, TRPV1
immunoﬂuorescence was partly associated with vGLUT
(vesicular glutamate transporter 1), a widely used marker of
glutamatergic nerve terminals28 (Figure 6a−d). By contrast,
TRPV1 immunoreactivity appeared to mostly not associate
Figure 2. Desensitization of rat TRPV1 and TRPV2 channels by CBDV and CBD: Bar graphs showing current density values upon the repeated
exposure to CBDV (10 μM) and CBD (10 μM) in HEK293 cells transiently expressing TRPV1 (a) and TRPV2 (b) channels. The second pulse was
given 5−10 min after the ﬁrst one. Each bar is the mean ± SEM of at least four separate determinations. *p < 0.05 vs the ﬁrst pulse.
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with vGAT (antivesicular GABA transporter), a common
marker of GABAergic neurons29 (Figure 6e−h). These
experiments suggest that TRPV1 is ideally located in the
hippocampal CA1 region to modulate also excitatory glutamate
release and signaling.
TRPV2 expression has been reported in the brain,30 but the
exact localization and function of this subclass of TRPV
channels have not been elucidated. Our results reveal that the
TRPV2 signal does not appear to be associated with either
presynaptic vGLUT or vGAT (Figure 6i−o), indicating that
TRPV2 channels are most likely expressed postsynaptically.
Interestingly, we also found that TRPV2 is robustly expressed
in what appears to be, morphologically, non-neuronal cells
(Figure 6o, white arrows). It remains to be conﬁrmed if these
cells are astrocytes, which have been recently reported to
express TRPV2.31
We next focused on TRPV1 channels and their presynaptic
role in determining neuronal excitability. Importantly, there is
the possibility that low levels of TRPV1 reported in the
aforementioned studies, are substantially upregulated in
conditions of hyperexcitability, such as epilepsy. Thus, recent
studies have shown that changes in TRPV1 expression and
activity facilitate epileptogenesis in patients aﬀected by mesial
temporal lobe epilepsy32 and that TRPV1 activation by
anandamide increases excitatory circuit activity in the
synaptically reorganized dentate gyrus.33 A more recent study
demonstrated that TRPV1 channels may be involved in the
development of electrical and PTZ-induced kindling.34 On the
other hand, PTZ-induced clonic seizures were reported to be
reduced in TRPV1 knockout mice.35 By contrast, to the best of
Figure 3. Eﬀects of CBDV and CBD in HEK293 transiently expressing
rat TRPV2 channels: Representative traces showing (a) CBDV (10−
30 μM) and (b) CBD (10−30 μM) eﬀects on rat TRPV2 current
density compared to control (vehicle). Eﬀects of (c) CBDV (3−30
μM) and (d) CBD (3−30 μM) on TRPV2 current expressed as
current density at a distinct range of membrane potentials.
Representative traces (upper panel) showing ruthenium red (RR; 10
μM) block of (e) CBDV (30 μM) and (f) CBDV (30 μM) eﬀects on
TRPV2 currents. The bottom panels in (f) and (g) show the
quantiﬁed data. Each bar is the mean ± SEM of at least four separate
determinations. *p < 0.05 vs vehicle.
Figure 4. Eﬀects of CBDV and CBD in HEK293 transiently expressing
rat TRPA1 channels: (a) Representative traces showing mustard oil
(MO; 100 μM) eﬀects in rat HEK293 TRPA1 current density
compared to control (vehicle). (b) CBDV (10−30 μM) and (c) CBD
(10−30 μM) eﬀects on TRPA1 current density compared to control
(vehicle). Eﬀects of (d) CBDV and (e) CBD on TRPA1 current
expressed as current density at a distinct range of membrane
potentials. Representative traces (upper panel) showing ruthenium
red (RR; 10 μM) block of (f) CBDV (30 μM) and (g) CBD (30 μM)
eﬀects on TRPV1 currents. The bottom panels in (f) and (g) show the
quantiﬁed data. Each bar is the mean ± SEM of at least four separate
determinations. *p < 0.05 vs vehicle.
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our knowledge, there has been no previous report of TRPV2 or
TRPA1 being directly associated with models of epileptiform
activity and acute seizure. These previous studies provide a
putative link between TRPV1 and some forms of seizure, and
thus prompted us to investigate here whether phytocannabi-
noid activation/desensitization of TRPV1 might result in the
modulation of neuronal hyperexcitability in vitro.
Capsaicin and CBDV Induce Changes in Hippocampal
Neuronal Activity: MEA Analysis. We next extended our
studies to electrophysiological ﬁeld potential recordings in
acute hippocampal brain slices using an in vitro model of
epileptiform activity. On the basis of our previous work which
showed that CBDV can suppress epileptiform activity in
hippocampal slices,7 and our present ﬁndings that (1) CBDV
Figure 5. Expression of TRPV1, TRPV2, and TRPA1 transcripts in rat hippocampal tissue: (a) Transcripts levels of TRPV1, TRPV2, and TRPA1
genes were evaluated in ipsalateral and contralateral sides of the rat hippocampus by qPCR analysis. The data are expressed by calculating the 2Δct
formula (see Methods). Each bar is the mean ± SEM of at least four separate determinations. *p < 0.05 vs TRPV1 mRNA expression level. (b)
Western blot analysis of TRPV1 and TRPV2 protein levels in hippocampal tissue. Representative blots showing the approximate molecular mass of
each TRPV protein (expressed in kDa) (upper) and quantiﬁcation of the averaged OD values for TRPV1 and TRPV2 normalized to those of α-
tubulin (lower) are shown. *P ≤ 0.05 vs TRPV1 protein expression level. Each data point is from at least four independent determinations.
Figure 6. Expression of TRPV1 and TRPV2 in adult rat hippocampal slices. Immunoﬂuorescence images, captured with a 40× objective, of rat
hippocampus sagittal cryosections. Red, TRPV1 or TRPV2 immunoreactivity; green, immunoreactivity of (a) vGLUT1 or (b) vGAT; blue, nuclei
identiﬁed with DAPI. Scale bar, 10 μm.
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exhibits high potency at TRPV1 in patch clamp measurements
and (2) there is signiﬁcant TRPV1 transcript expression in rat
hippocampal slices, we compared the eﬀects of CBDV with
those of the prototypical TRPV1 agonist, capsaicin, upon
epileptiform activity. Speciﬁcally, we measured the eﬀect of
CBDV and capsaicin on epileptiform activity induced by
exposure of acute, hippocampal brain slices to Mg2+-free
solution measured using multielectrode array (MEA) electro-
physiological ﬁeld potential recordings. To determine whether
acute CBDV has any eﬀect in this system and to assess the
potential contribution of activation/desensitization of TRPV1
channels both to the eﬀects of CBDV and to the epileptiform
activity observed, we studied the eﬀects of (1) DMSO
(vehicle), (2) 10 μM capsaicin, (3) the selective TRPV1
antagonist iodoresiniferatoxin (IRTX; 1 μM),36 (4) CBDV (10
μM), and (5) CBDV or capsaicin (10 μM) in the presence of
IRTX (1 μM), upon epileptiform activity. Since these
experiments were performed in native tissue, as opposed to
recombinant HEK293 cells overexpressing only a single TRP
channel isoform, IRTX was used since it provides a more
selective block of TRPV1 than capsazepine.
Overall, there was a statistically signiﬁcant eﬀect of drug
treatment (H(4) = 55.62, p ≤ 0.0001; Figure 7a) on
epileptiform burst amplitude, which was signiﬁcantly decreased
by (1) capsaicin (71% of control; p ≤ 0.001; n = 25 electrodes
from 4 slices), in a manner antagonized by IRTX, (2) CBDV
(74% of control; p ≤ 0.001; n = 33 electrodes from 5 slices),
and (3) CBDV plus IRTX (69% of control; p ≤ 0.001; n = 34
electrodes from 5 slices). IRTX alone had no signiﬁcant eﬀect
on burst amplitude (84% of control; n = 25 electrodes from 4
slices), but diﬀered signiﬁcantly when compared to capsaicin (p
≤ 0.01). There was also a statistically signiﬁcant diﬀerence
between the eﬀects of drug treatments on burst duration (H(4)
= 19.79, p = 0.0005; Figure 7b), where burst duration was
signiﬁcantly decreased by CBDV (to 87% of control; p ≤ 0.001;
n = 33 electrodes from 5 slices). No other drug treatment
produced a signiﬁcant eﬀect on burst duration. When applied
together, IRTX counteracted the eﬀect of CBDV only on
duration and not amplitude of neuronal bursts (Figure 7a and
b). Finally, there was no statistically signiﬁcant diﬀerence
between eﬀects of drug treatments on burst frequency (H(4) =
7.69. p = 0.1036; Figure 7c), although this is an intrinsically
variable measure.37 Representative traces are shown in
Supporting Information Figure 2. These data indicate that
while capsaicin and CBDV exert similar eﬀects on epileptiform
burst amplitude, unlike capsaicin, CBDV eﬀects on burst
amplitude were not sensitive to IRTX. Interestingly, while
IRTX did attenuate the CBDV-induced decrease in epilepti-
form burst duration, capsaicin alone had no eﬀect upon burst
duration. Together, these data suggest that CBDV eﬀects in the
Mg2+-free model of epileptiform activity are not uniquely
mediated via activation of TRPV1.
It has already been established that the phytocannabinoid
CBDV exerts antiepileptiform properties in the Mg2+-free
model,8 whereby CBDV (at 10 and 100 μM) signiﬁcantly
reduced burst amplitude and duration in the CA1 area of the
hippocampus, where such measures are most indicative of drug
eﬀects in this system.37 In those experiments, 30 min after
epileptiform activity commenced, CBDV was applied and
allowed to equilibrate for a further 30 min before recordings
were made. For the experiments described here, CBDV was
instead added acutely (10 min exposure) and produced similar
eﬀects. These data, therefore, conﬁrm and extend our previous
ﬁndings demonstrating that CBDV is antiepileptiform in the
Mg2+-free model.
Figure 7. Eﬀects of TRPV1 ligands and CBDV on epileptiform burst
amplitude, duration, and frequency in acute hippocampus CA1.
Epileptiform activity was induced by application of Mg2+-free ACSF
solution for 30−40 min before control recordings were taken. Drugs
were applied in the presence of Mg2+-free solution, and recordings
taken after 1 min. Eﬀects of vehicle (DMSO), TRPV1 agonist
capsaicin (CAPS; 10 μM; n = 25 electrodes from 4 slices from 2 rats),
selective TRPV1 antagonist iodoresiniferatoxin (IRTX; 1 μM; n = 25
electrodes from 4 slices from 4 rats), CBDV (10 μM; n = 33 electrodes
from 5 slices from 3 rats), and CBDV or capsaicin in the presence of
IRTX (10 μM and 1 μM, respectively; n = 34 electrodes from 5 slices
from 3 rats). Neuronal burst (a) amplitude, (b) duration, and (c)
frequency are normalized to their own control. Maximum 0.1%
DMSO present. Data represents median with interquartile range and
analyzed by Kruskal−Wallis test with Dunns multiple comparison
post hoc (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001).
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Capsaicin, a TRPV1 agonist, also signiﬁcantly reduced burst
amplitude, which we use as the most relevant measure of
epileptiform activity in the present study (see ref 37); such
antiepileptiform action was antagonized by IRTX, which may
reﬂect activation and desensitization of TRPV1, as per our
reported eﬀects in recombinant HEK293 cells above. Thus, the
eﬀect of capsaicin might be due to desensitization of
endogenously activated TRPV1 channels participating in
Mg2+-free-induced neuronal hyperactivity, as assessed by
MEA. However, the lack of eﬀect of IRTX on CBDV-induced
reduction of burst amplitude seems to rule against this
possibility for CBDV. A diﬀerent approach, described in the
next section, was used to determine whether TRPV1 is tonically
activated under Mg2+-free conditions in rat hippocampal tissue,
and may become desensitized following treatment with
capsaicin and CBDV.
CBDV signiﬁcantly reduced the duration of epileptiform
bursts and was, in fact, the only compound to do so with this
experimental design. Interestingly, in the presence of IRTX,
CBDV eﬀects on burst duration were attenuated. This may
suggest that TRPV1 is, in part, implicated in the duration
component of CBDVs antiepileptiform activity. However, it
must be noted that if this was the case then capsaicin would
also be expected to reduce burst duration. CBDV has been
reported to be a weaker agonist of TRPV1 than capsaicin.14
Thus, for now, it is only pertinent to observe that both
compounds share one common eﬀect. Further MEA experi-
ments with a range of capsaicin and CBDV concentrations will
be useful to reach a deﬁnitive conclusion as to whether the
eﬀects of capsaicin and CBDV are at least in part mediated by a
similar mechanism, and whether such mechanism involves
TRPV1 activation/desensitization.
The Mg2+-free model produces spontaneous, synchronous
neuronal discharges in acute brain slices that are comparable to
the bioelectrical activity observed during status epilepticus.37
Despite this, it is important to note that this model is not fully
representative of conditions found in an epileptic brain since
the neurodegeneration, inﬂammation, synaptic reorganization,
and altered protein expression found in epileptic brain cannot
be emulated in acute tissue slices. Here, we focused on the
potential eﬀects of CBDV on TRPV1 channels in the Mg2+-free
model; in the future, it will be important to extend studies to
other TRP isoforms, in particular, TRPV2, and to other in vitro
and in vivo seizure models, to more fully explore how the clear
eﬀects of phytocannabinoids on TRP activation/desensitization
may relate to their anticonvulsant actions.
CBDV Exposure Reduces the Phosphorylation of
TRPV1 Channels in the Hippocampus of Epileptic Rats.
Changes in TRPV1 expression and/or phosphorylation have
been associated with several neurological disorders at both the
peripheral and central level.38,39 In particular, phosphorylation
has been shown to be required for TRPV1 sensitization and
cation gating, whereas dephosphorylation is known to
desensitize this channel.40 TRPV1 has two well-known sites
for PKC-mediated phosphorylation: S502 and S800.40 We
therefore tested whether the changes in the neuronal activity
induced by capsaicin and CBDV, as observed in MEA
experiments under our experimental conditions, were asso-
ciated with changes in TRPV1 phosphorylation at S800. To this
purpose, we performed Western blot analysis using anti-TRPV1
and anti-phospho-TRPV1 (pTRPV1) speciﬁc antibodies. As
shown in Figure 8a, the expression of TRPV1 was not
signiﬁcantly altered in rat hippocampal slices after 1 h exposure
to artiﬁcial cerebrospinal ﬂuid (ACSF) in the presence (control
condition) or absence (epileptiform condition) of Mg2+.
Quantitative analysis of TRPV1 and pTRPV1 was determined
relative to the corresponding levels of α-tubulin and TRPV1,
respectively (Figure 8b and c). In control slices, we found that
10 μM capsaicin or 10 μM CBDV, but not 1 μM IRTX, tended
to increase phosphorylation at the S800 site of TRPV1 (Figure
8a, left panel), which could suggest the activation of this
channel. However, none of the eﬀects reached statistical
signiﬁcance (Figure 8b). On the other hand, in Mg2+-free
solutions, we observed a signiﬁcant increase in the pTRPV1
signal (Figure 8c, right panel). These data are consistent with
the proposal that neuronal excitability correlates with increased
TRPV1 activity. Here, increased excitability may both cause and
be caused by TRPV1 activity via increased depolarization.
Interestingly, in hippocampal slices exposed to Mg2+free ACSF,
coincubation with capsaicin and CBDV, resulted in a
statistically signiﬁcant reduction of the pTRPV1 signal (Figure
Figure 8. Evaluation of TRPV1 phosphorylation in hippocampal slices
upon CBDV exposure TRPV1 protein expression and changes in its
phosphorylation at S800 were evaluated through Western blot analysis
of hippocampal slices exposed for about 1 h to ACSF in the presence
(a, control condition) or absence of Mg2+ (b, epileptic-like condition),
and either capsaicin (CAPS; 10 μM); iodoresiniferatoxin (IRTX; 1
μM); CBDV (10 μM) or CBDV + 1 μM IRTX. (b) Bar graph showing
the quantiﬁcation of TRPV1 levels normalized to α-tubulin. (c)
Quantiﬁcation of phospho-TRPV1 (pTRPV1) levels normalized to
total TRPV1. *p ≤ 0.05 vs respective control; data from three separate
samples.
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8c, right panel). In Mg2+-free conditions, IRTX alone also
reduced TRPV1 phosphorylation (Figure 8a). The intensity of
the band corresponding to total TRPV1 was unchanged (Figure
8a). Quantitative analysis of pTRPV1 expression is reported
relative to the corresponding total TRPV1 expression (Figure
8c). Collectively, these data suggest that, under conditions in
which epileptiform activity is induced in rat hippocampal slices
by Mg2+-free solution, a stronger phosphorylation of TRPV1 is
observed, which is indicative of TRPV1 sensitization. Under
these conditions, both capsaicin and CBDV treatment
signiﬁcantly reduce phosphorylation, thereby potentially
leading to TRPV1 desensitization. Thus, despite the fact that
our pharmacological data do not support the full involvement
of TRPV1 in the action of CBDV in this model, this channel
might still participate in the eﬀects of this compound.
Furthermore, these data also suggest that CBDV capability of
inducing fast TRPV1 desensitization may oﬀer a new
opportunity to treat human neurological disorders caused by
alteration of TRPV1-mediated conductances, such as epilepsy.
However, given the fact that TRPV1 can be modulated by
changes in the membrane potential, we cannot rule out the
possibility that CBDV and capsaicin-induced TRPV1 dephos-
phorylation is the consequence, rather than the cause, of CBDV
and capsaicin-induced reduction of neuronal hyperexcitability.
■ CONCLUSIONS
We demonstrate here that (1) two nonpsychotropic
phytocannabinoids, CBD and CBDV, act as direct agonists
and desensitizers of recombinant rat TRPV1, TRPV2, and
TRPA1, and that these channels are expressed to a varying
extent in rat hippocampal slices; (2) CBDV and capsaicin
produce similar, although not identical, eﬀects upon epilepti-
form activity induced in rat hippocampal slices, as assessed by
MEA measurements; (3) capsaicin and CBDV are capable of
dephosphorylating rat hippocampal TRPV1 in slices kept in a
Mg2+-free solution, thus potentially leading to its desensitiza-
tion, and to the counteraction of TRPV1 participation in
neuronal hyperexcitability. In the future, it will be important to
extend the study of phytocannabinoid TRP channel agonists to
diverse in vitro and in vivo models of epilepsy.
■ METHODS
Cell Culture, Reagents, and Transient Transfection. Human
embryonic kidney 293 (HEK293) cells were grown in Dulbeccos
modiﬁed Eagles medium supplemented with 10% fetal bovine serum
(FBS), 50 U/mL penicillin plus 50 mg/mL streptomycin, and 1% L-
glutamine in a humidiﬁed atmosphere of 95% O2/5% CO2 at 37 °C.
Cells were transiently transfected with plasmids encoding rat TRPV1,
TRPV2, or TRPA1 cDNAs using Lipofectamine LTX (Gibco
Invitrogen, Paisley, U.K.) according to the manufacturers instructions.
A plasmid encoding for the enhanced green ﬂuorescent protein
(eGFP) was used as a transfection marker.
Patch Clamp Electrophysiology. HEK293 cells transiently
expressing rat TRPV1, rat TRPV2, or rat TRPA1 were plated onto
poly-L-lysine coated glass coverslips, maintained in 5% CO2 at 37 °C,
and used 24−48 h after transfection. Recordings from TRP-expressing
HEK293 cells were performed using the whole-cell patch clamp
technique. Control and test solutions were applied to cells at 0.5 mL/
min via a gravity-fed perfusion system. Recordings were performed at
room temperature (20−22 °C). Currents were sampled at 10 kHz,
ampliﬁed, and ﬁltered at 2 kHz using a Digidata 1200 and Axopatch
200B ampliﬁer and analyzed using pClamp 9.0. CBD- or CBDV-
activated currents were elicited with a 600 ms voltage ramp from −80
to +80 mV at a sampling rate of 10 kHz from a holding potential of
−80 or −100 mV. The extracellular solution contained the following
(in mM): NaCl (132), KCl (5.4), CaCl2 (1.8), MgCl2 (0.8), HEPES
(10), and glucose (10) at pH 7.4. The pipet solution contained the
following (in mM): CsCl (45), CsF (100), EGTA (5), HEPES (10),
and glucose (5) at pH 7.4.
mRNA Extraction and Quantitative PCR (qPCR) Analysis.
Total RNA was isolated from native tissues by use of the TRI-Reagent
(Life Technology, Milan, Italy), reacted with DNase-I (1U/μL; Sigma-
Aldrich) following the manufacturers instruction, and then quantiﬁed
by spectrophotometric analysis. Both sides of the hippocampus were
analyzed. Final preparation of RNA was considered DNA- and protein-
free if the ratio between readings at 260/280 nm was >1.7. The
puriﬁed mRNA was reverse-transcribed by use of reverse transcriptase
(enzyme-VILO) (Life Technology, Milan, Italy). Quantitative real-
time PCR was carried out in CFX384 real-time PCR detection system
(Bio-Rad, Segrate MI, Italy) with speciﬁc primers (see Supporting
Information Table 1) by the use of SYBR Green detection (Bio-Rad,
Segrate MI, Italy). Samples were ampliﬁed simultaneously in
quadruplicate in one assay run with a nontemplate control blank for
each primer pair to control for contamination or primer-dimers
formation, and the ct (cycle threshold) value for each experimental
group was determined. The housekeeping genes (the ribosomal
protein S16) has been used as an internal control to normalize the ct
values, using the 2−ΔCt formula; diﬀerences in mRNA content between
groups were as expressed as 2−ΔΔct, as previously described.41
Immunoﬂuorescence. Adult male rats were deeply anesthetized
and then perfused/ﬁxed with freshly made paraformaldehyde (4% w/
v) for 5 min. Whole brains were removed from the skull and postﬁxed
in the same ﬁxative for 2 h at 4 °C, and then transferred to phosphate-
buﬀered saline (PBS, pH 7.4). Forebrain sagittal vibratome sections
(100 μm) were cut. Free-ﬂoating sections were incubated overnight at
4 °C with the following primary antibodies: (i) mouse monoclonal
anti-TRPV1 antibody (1:100 UC Davis/NIH NeuroMab Facility,
CA); (ii) rabbit polyclonal anti-TRPV2 antibody (1:100 Novus
Biologicals, LLC); (iii) guinea-pig polyclonal anti-vGLUT1 (iiii)
vGAT antibodies (1:250 Synaptic System Inc. Japan). DAPI 1:500
(Sigma-Aldrich, Segrate MI, Italy). All antibodies were diluted in PBS
containing 10% (v/v) fetal bovine serum and 0.1% Triton X-100.
Slices were then washed in PBS and incubated at 20−22 °C for 1 h in
a mixture containing two ﬂuorescent secondary antibodies (Alexa
ﬂour, Life Tecnologies): (i) chicken anti-mouse or -rabbit 594 for anti-
TRPV1 and -TRPV2; (ii) donkey anti-guinea pig 488 for anti-vGLUT
and -vGAT. Images were acquired by using the digital camera JVC
TK-1381 connected to the microscope and the image analysis software
AxioVision PlusR 4.0 for Windows (Carl Zeiss, Goettingen, Germany).
Western Blot Analysis. Each animal, previously anesthetized, was
decapitated, and the brain quickly removed to prepare hippocampal
slices (see section below). The hippocampal slices were exposed to
artiﬁcial cerebrospinal ﬂuid (ACSF) ± MgSO4, comprising (mM)
NaCl (124), KCl (3), KH2PO4 (1.25), NaHCO3 (36), D-glucose (10),
CaCl2 (1) in ﬁve distinct conditions: (1) ACSF + DMSO; (2) ACSF +
10 μM capsaicin; (3) ACSF + 1 μM IRTX; (and 4) ACSF + 10 μM
CBDV; (5) ACSF + 10 μM CBDV + 1 μM IRTX. After this time, the
slices were homogenized in lysis solution (150 mM NaCl, 1 mM
EDTA, 1% (v/v) TritonX100, 2.5 mM sodium pyrophosphate, 1 mM
b-glycerophosphate, 1 mM Na3VO4, 20 mM Tris-HCl, pH 8, 1% SDS,
plus protease inhibitors) at pH 7.4. Lysates were boiled for 5 min in
Laemmli SDS loading buﬀer, loaded (70 μg) on 10% SDS-
polyacrylamide gel electrophoresis, and then transferred to a PVDF
membrane. Filters were incubated overnight at 4 °C with the following
antibodies: (a) monoclonal anti-TRPV1 clone N221/17 (dilution
1:500 Antibodies Inc.; Davis, CA); (b) polyclonal rabbit anti-
phospospeciﬁc TRPV1 (pTRPV1 S800) (dilution, 1:500; Abnova,
Heidelberg Germany). The monoclonal antitubulin clone B-5-1-2
(dilution, 1:5000; Sigma-Aldrich, Milan IT) was used to check for
equal protein loading. Reactive bands were detected by chemilumi-
nescence (ECL or ECL-plus; PerkinElmer, Milan IT). Images were
analyzed on a ChemiDoc station with Quantity-one software (Bio-
Rad, Segrate MI, Italy).
Multielectrode Array Recordings from Acute Hippocampal
Brain Slices. Tissue Preparation. The housing and use of animals in
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all experiments were carried out in accordance with U.K. Home oﬃce
regulations (Animals in Scientiﬁc Procedures Act, 1986). Adult male
Wistar Kyoto rats (P24-28; Harlan, Bicester, U.K.) were sacriﬁced by a
Schedule 1 method (terminal isoﬂurane inhalation with death
conﬁrmed by cervical dislocation). Each brain was quickly removed
and placed immediately in ice-cold, carboxygenated (95% O2: 5%
CO2) artiﬁcial cerebrospinal ﬂuid (ACSF), comprising (mM) NaCl
(124), KCl (3), KH2PO4 (1.25), NaHCO3 (36), D-glucose (10),
MgSO4·6H2O (1), and CaCl2 (2). Transverse hippocampal brain slices
(400 μm) were taken using a Vibroslice 725 M instrument (Campden
Instruments Ltd., Loughborough, U.K.) and stored in carboxygenated
ACSF at room temperature for a minimum of 1 h before use.
Multielectrode Array Recordings. MEA recordings were performed
largely as previously described.37 Brieﬂy, extracellular neuronal activity
in the hippocampus was monitored and recorded using multielectrode
arrays (MEAs; 59 electrodes, each 30 μm diameter with 200 μm
spacing; Multi Channel Systems GmbH, Reutlingen, Germany). Prior
to recording, MEAs were cleaned with 5%w/v Terg-A-Zyme (Cole-
Palmer, U.K.), rinsed with distilled water, allowed to dry, and gently
wiped with a cotton bud dipped in methanol. Hippocampal slices were
transferred to MEAs and held in place using a ﬁne mesh anchor to
ensure stability and contact with the electrode array. A Nikon TS-51
microscope (Nikon, Japan; magniﬁcation ×4) was used to carefully
position the slice to ensure that the CA1 region lay over the electrode
array. Slices were continuously perfused (∼2 mL/min) with
carboxygenated ACSF at 25 °C. Slice viability and contact were
assessed by application of biphasic bipolar voltage stimuli (0.5−1 V;
STG2004 stimulator, Multi Channel Systems GmbH, Reulingen,
Germany) at electrodes located at the Schaﬀer collateral pathway to
evoke local ﬁeld potentials in the CA1 region. Signals were ampliﬁed
(1200× gain), band-pass ﬁltered (10−3200 Hz) by a 120-channel dual
headstage ampliﬁer (MEA60 system, Multi Channel Systems GmbH,
Reutlingen, Germany), and simultaneously sampled at 1000 Hz on all
channels. Data acquisition was to a PC using MC_Rack software
(Multi Channel Systems GmbH, Reutlingen, Germany) to monitor
and record data for oﬄine analysis.
Mg2+-Free Model of Epileptiform Activity. To induce epileptiform
activity, slices were perfused with ACSF with MgSO4·6H2O omitted
without substitution (Mg2+-free ACSF) for 30−40 min. Spontaneous
ictal-like bursting activity was then recorded continuously for 10 min.
Drugs were applied by dissolving previously prepared aliquots of
concentrated stock solutions in the perfused Mg2+-free ACSF. As the
TRPV1 receptor is rapidly desensitized following activation, once the
drug reached the brain slice (∼1 min), 10 min of recording ictal bursts
in the presence of the drug was performed. Drugs used in these
experiments were capsaicin (CAPS; 10 μM; in DMSO; Tocris),
iodoresiniferatoxin (IRTX; 1 μM; in DMSO; Tocris), and
cannabidivarin (CBDV; 10 μM; in DMSO; GW). No more than
0.1% DMSO was present in the ACSF during experiments. No more
than two brain slices from each animal were subjected to the same
drug treatment.
Data Analysis. Up to seven electrodes from the CA1 region of each
brain slice were selected for analysis; the typical number covering the
CA1 region in this slice preparation. For each electrode, the last 10
bursts from each 10 min recording period were identiﬁed using
Neuroexplorer (Nex Technologies, Littleton, MA). Using a similar
method of analysis as previously described,37 the amplitude and
duration of each of these 10 bursts were manually measured by
playback of data in MC_Rack (Multi Channel Systems GmbH,
Reutlingen, Germany). The same 10 bursts were also used to calculate
burst frequency where frequency (Hz) = 10/(time of last burst − time
of ﬁrst burst). Individual values for burst amplitude, duration and
frequency for each electrode were entered in Microsoft Excel
(Microsoft, Redmond, WA) and pooled. Data were then normalized
by expressing the drug-treated parameters as a percentage of starting
control (where the magnitude of a given measure when no drug was
present = 100%) and was graphically represented as median with
interquartile range. A Kruskal−Wallis one-way analysis of variance
with Dunns multiple comparison posthoc tests was performed using
GraphPad Prism (v5, GraphPad Software Inc., La Jolla, CA), and
posthoc comparisons conducted using a Mann−Whitney U test.
Statistically signiﬁcant diﬀerences were accepted at p < 0.05.
Reagents. CBD and CBDV (a kind gift of GW Pharmaceuticals
Ltd., Salisbury, U.K.) were stored at −20 °C as a 100 mM stock
solution in dimethyl sulfoxide, which was diluted into the extracellular
solution to a ﬁnal working concentration on the day of use. TRPV1
agonist capsaicin, the TRPV1 antagonists capsazepine and iodor-
esiniferatoxin (IRTX) (all Tocris Bioscience, Bristol, U.K.), the
TRPA1 agonist mustard oil, and the nonselective antagonist
ruthenium red (Sigma, Poole, UK) were used.
Other Statistical Analyses. Unless otherwise stated (see MEA
section), data were expressed as means ± SEM of the given number of
experiments (n). Data sets were compared by use of matched
Students t tests or, if necessary, with one-way analysis of variance,
followed by the Newman−Keul test. Statistically signiﬁcant diﬀerences
were accepted at p < 0.05.
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